Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines
about
The use of sensitive chemical antibodies for diagnosis: detection of low levels of EpCAM in breast cancerActivator protein 1 (AP-1) contributes to EpCAM-dependent breast cancer invasion.Effects of EpCAM overexpression on human breast cancer cell linesA general approach for receptor and antibody-targeted detection of native proteins utilizing split-luciferase reassembly.The novel EpCAM-targeting monoclonal antibody 3-17I linked to saporin is highly cytotoxic after photochemical internalization in breast, pancreas and colon cancer cell lines.Computational design optimization for microfluidic magnetophoresisAn anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells.Construction, expression, and characterization of a recombinant immunotoxin targeting EpCAM.Recombinant chimeric antibody hCAb as a novel anti-human colorectal carcinoma agentGlycoengineered Monoclonal Antibodies with Homogeneous Glycan (M3, G0, G2, and A2) Using a Chemoenzymatic Approach Have Different Affinities for FcγRIIIa and Variable Antibody-Dependent Cellular Cytotoxicity Activities.Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy.Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer.Tubocapsanolide A inhibits transforming growth factor-beta-activating kinase 1 to suppress NF-kappaB-induced CCR7.Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilarThe role of the complement system in cancer.Isolation of viable cancer cells in antibody-functionalized microfluidic devices.Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesotheliomaCapture of esophageal and breast cancer cells with polymeric microfluidic devices for CTC isolationTargeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma.Enhanced Isolation and Release of Circulating Tumor Cells Using Nanoparticle Binding and Ligand Exchange in a Microfluidic Chip.CD55 and CD59 expression protects HER2-overexpressing breast cancer cells from trastuzumab-induced complement-dependent cytotoxicity.Integrin receptors on tumor cells facilitate NK cell-mediated antibody-dependent cytotoxicity.Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses.Highly efficient capture of cancer cells expressing EGFR by microfluidic methods based on antigen-antibody association
P2860
Q28486906-67F28705-71E8-4127-96AA-A528B78E203CQ30427356-819E1147-7FB8-425D-A728-E62D4B47087EQ33807783-F62FF0E4-D39A-4FA8-9707-7A67317CC714Q34204188-E660D886-318E-433A-852C-CC375DD35BD2Q34223880-4A3E2763-1498-4A82-98C5-3AB342C2B85EQ34869844-D1D221D3-08AB-4A8D-873F-35C9C416875DQ34923734-F8A183D1-DFF1-4DF1-BC7A-7FD590A4F1FBQ35556641-6320A5E0-F561-4CFC-B808-2B58AFE25C43Q35586920-1CBA16B0-9D58-4A7D-9943-FC8063355A55Q35705039-93E17DB7-68C6-4D37-92BA-516808A3D941Q36417330-62F27F05-4C9B-459E-A083-32F99BF82CA6Q36613499-A2AD5CEF-82E6-454A-A507-F44223D51049Q38214511-5C59DD77-2908-43B4-9226-75E3E0B91BD1Q38358496-C980D6F6-45C7-40A9-88AC-43A57E4FB40CQ38906179-3117E1DE-CEEF-47B1-B88C-2E4169F84EB6Q39156024-0216DFA7-7163-4BD0-BE5B-D201146D3222Q39182108-ABAD6CE9-58E8-4AF6-8B8B-918FA1B5AFAAQ39290976-FE1506D5-5604-4709-9CDE-2BDD6E44FBBBQ39643263-B23CECCC-506B-473A-9418-A4E7038B8406Q39733328-09B2E5D8-0751-47E6-88C2-D34C0CCE2819Q40988469-78E0F220-3361-4381-9747-858506165418Q41612157-2D54B9A3-5D49-4192-9C59-0E10D9998411Q42544946-FA633839-C41C-4AA7-A4DF-06ABC75D3FCFQ52684751-A0A09F6E-0375-4DBE-B078-6461936201B4Q58786937-82FF4E58-2FC3-4954-ABC4-4CE752D647ED
P2860
Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Cellular and complement-depend ...... ainst breast cancer cell lines
@ast
Cellular and complement-depend ...... ainst breast cancer cell lines
@en
Cellular and complement-depend ...... ainst breast cancer cell lines
@nl
type
label
Cellular and complement-depend ...... ainst breast cancer cell lines
@ast
Cellular and complement-depend ...... ainst breast cancer cell lines
@en
Cellular and complement-depend ...... ainst breast cancer cell lines
@nl
prefLabel
Cellular and complement-depend ...... ainst breast cancer cell lines
@ast
Cellular and complement-depend ...... ainst breast cancer cell lines
@en
Cellular and complement-depend ...... ainst breast cancer cell lines
@nl
P2093
P2860
P356
P1476
Cellular and complement-depend ...... ainst breast cancer cell lines
@en
P2093
A J da Silva
K Brischwein
P A Baeuerle
S Preithner
P2860
P2888
P356
10.1038/SJ.BJC.6602310
P407
P577
2005-01-31T00:00:00Z
P5875
P6179
1028096782